Business Context and Reporting Period
Company: Geron Corporation (GERN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapies for cancer and chronic degenerative diseases (spinal cord injury, heart failure, diabetes). Its strategy relies on two primary technology platforms: Telomerase (targeting the enzyme for cancer treatment via inhibitors and vaccines) and Human Embryonic Stem Cells (hESCs) (for regenerative medicine). The company has no commercial therapeutic products and relies on licensing revenue and capital markets for funding.
Key Financial Metrics
| Metric (in thousands) | 2009 | 2008 |
|---|---|---|
| Total Revenues | $1,726 | $2,803 |
| Operating Expenses | $71,960 | $69,847 |
| Net Loss | $(70,184) | $(62,021) |
| Net Loss per Share (Basic/Diluted) | $(0.80) | $(0.79) |
| Cash, Cash Equivalents & Marketable Securities | $167,070 | $163,655 |
| Working Capital | $110,324 | $160,535 |
| Accumulated Deficit | $(577,267) | $(506,893) |
Revenue Breakdown (2009): Revenues from collaborative agreements were $450,000 (primarily GE Healthcare), and license fees/royalties were $1,276,000.
Expense Breakdown (2009): Research and Development (R&D) expenses were $57.6 million (Oncology: $29.5M; hESC Therapies: $28.1M). General and Administrative (G&A) expenses were $14.3 million.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 38% from $2.8 million in 2008 to $1.7 million in 2009. This was driven by a significant drop in license fee revenue ($2.5M in 2008 vs. $1.3M in 2009), as 2008 included a $1.5M milestone payment from Exeter Life Sciences and 2007 included $5.0M from Merck.
- Increased Net Loss: Net loss increased by approximately 13% to $70.2 million. This was primarily due to decreased interest income (falling rates), reduced milestone revenues, and increased R&D expenses.
- R&D Expense Increase: R&D expenses rose 7% to $57.6 million, attributed to higher personnel costs ($2.3M increase) and increased clinical trial costs ($0.8M increase) for imetelstat and GRNVAC1.
- Liquidity: Cash and marketable securities increased slightly to $167.1 million, bolstered by $45.9 million in net proceeds from a February 2009 public offering and $3.6 million from a private placement in September 2009.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Cash Runway: Management estimates existing capital resources are sufficient to fund operations through at least December 2011.
- Clinical Milestones: The company plans to advance its lead telomerase inhibitor, imetelstat, to Phase II trials in four malignancies in 2010. The Phase II trial for the telomerase vaccine (GRNVAC1) in Acute Myelogenous Leukemia (AML) completed enrollment in December 2009.
- Deferred Revenue: The company expects to recognize $700,000 in 2010 and $350,000 in 2011 from existing deferred revenue.
Material Risks and Contingencies
- GRNOPC1 Clinical Hold: The Phase I clinical trial for GRNOPC1 (hESC-derived therapy for spinal cord injury) is on clinical hold by the FDA. This occurred after a preclinical expansion study showed a higher frequency of cysts in animals than previously observed. The company is conducting confirmatory studies to resolve the hold.
- Capital Needs: The company has a history of losses and anticipates future losses. It will require substantial additional capital to continue operations and develop product candidates. Failure to secure funding could force curtailment of programs.
- Intellectual Property: The company faces patent opposition proceedings in Europe and Australia regarding telomerase and hESC technologies. A 2008 European Patent Office decision regarding WARF patents (licensed to Geron) limited protection for hESC-based products in Europe, though Geron argues its specific filings are distinct.
- Stock-Based Compensation: Significant non-cash expenses were recorded for stock-based compensation ($10.6M in 2009) and deemed dividends on warrant modifications ($0.19M in 2009).
Investor Verification Checklist
- GRNOPC1 Status: Verify the timeline and results of the confirmatory preclinical study required to lift the FDA clinical hold on the spinal cord injury trial.
- Imetelstat Phase II: Confirm the initiation dates and patient enrollment progress for the planned Phase II trials in 2010.
- GRNVAC1 Data: Monitor the release of final data from the completed Phase II AML trial to assess efficacy and potential for further development.
- Cash Burn Rate: Track quarterly cash usage to ensure the runway through late 2011 remains valid given the high R&D spend.
- Patent Litigation: Review updates on the European patent opposition proceedings involving Pharmexa and the status of hESC patentability in Europe.